Oxford Biomedica Plc (OXBL)

335.25p
   
  • Change Today:
      7.75p
  • 52 Week High: 471.50
  • 52 Week Low: 166.60
  • Currency: UK Pounds
  • Volume: 5,412

OXBL Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

Key Personnel

CEO: Frank Mathias
CFO: Stuart Paynter
Chairman and CEO: Roch Doliveux
Independent Non-Executive Director: Heather Preston
Independent Non-Executive Director: Leone Patterson
Independent Non-Executive Director: Catherine Moukheibir
Independent Non-Executive Director: Namrata P Patel
Senior Independent Director: Dame Kay Davies
Vice Chairman: Stuart Henderson
Non-Executive Dir: Michael Hayden, Robert Ghenchev, Peter Soelkner

Contact Details

Address: Windrush Court, Transport Way, Oxford, United Kingdom, OX4 6LT
Phone: +44 (0) 1865 783 000
Fax: +44 (0) 1865 783 001
Website: http://www.oxb.com/

Listings

Overseas Listings: LSE:OXB
ISIN: GB0006648157

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 5 minutes.

 

OXBL Market Data

Currency UK Pounds
Share Price 335.25p
Change Today 7.75p
% Change 2.37 %
52 Week High 471.50
52 Week Low 166.60
Volume 5,412

Trades for 21-May-2024

Time Volume / Share Price
16:01 823 @ 336.00p
16:01 88 @ 336.00p
16:01 53 @ 336.00p
16:01 413 @ 336.00p
16:01 20 @ 336.00p

OXBL Key Personnel

CFO Stuart Paynter
CEO Frank Mathias

Top of Page